<DOC>
	<DOC>NCT00150540</DOC>
	<brief_summary>The purpose of this study is to assess the safety of lanthanum carbonate in patients undergoing dialysis who have received lanthanum carbonate in the previous studies and wish to continue treatment.</brief_summary>
	<brief_title>A Long Term Study of Lanthanum Carbonate in Patients Requiring Dialysis Who Have Ived Lanthanum Carbonate in Previous Studies Defined by the Protocol.</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<criteria>Patients who participated in LAMIV301, LAMIV303, LAMIV307 OR LAMIV308 and received lanthanum carbonate Patients must continue to require treatment with a phosphate binder for hyperphosphatemia male or nonpregnant female who agrees to use an effective contraceptive method while on study treatment and for 30 days thereafter Patients withdrawn from LAMIV301, LAMIV303 OR LAMIV307 prior to randomization Patients withdrawn from LAMIV301, LAMIV303, LAMIV307 OR LAMIV308 due to adverse events termed "possible" or "related" to study medication Pregnant or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
</DOC>